You just read:

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

News provided by

SillaJen, Inc.

Sep 04, 2018, 09:00 ET